Action RCUS ARCUS BIOSCIENCES, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Arcus Biosciences, Inc.

Actions

RCUS

US03969F1093

Marché Fermé - Nyse
Autres places de cotation
 22:00:02 16/07/2024 		Varia. 5j. Varia. 1 janv.
15,89 USD +3,05 % Graphique intraday de Arcus Biosciences, Inc. +12,86 % -16,81 %
09/07 Arcus Biosciences annonce que Taiho a exercé son option pour une licence exclusive sur le quémliclustat au Japon MT
05/07 Mise à jour sectorielle : Les actions du secteur de la santé progressent dans l'après-midi MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Liver Cancer Pipeline 2024 | Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics
AQ
Arcus Biosciences Announces New Employment Inducement Grants
BU
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
BU
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
BU
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
BU
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
BU
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
ARC-9: A Randomized Study to Evaluate Etrumadenant Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC) - Form 8-K
PU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
BU
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
BU
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
BU
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Arcus Biosciences Announces New Employment Inducement Grants
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action RCUS
  4. Actualités Arcus Biosciences, Inc.
  5. Communiqués